title: Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
abstract: We report the case of a 57-year old female patient with refractory to treatment pyoderma gangrenosum associated with clinically inactive Crohn's disease. Pyoderma gangrenosum was successfully treated with Infliximab, a chimeric monoclonal antibody that inhibits tumour necrosis factor alpha (TNF-alpha). Our case report suggests that Infliximab, a therapeutic agent for refractory and fistulizing Crohn's disease, may also be safe and effective in the treatment of Crohn's disease associated pyoderma gangrenosum, even though the inflammatory bowel disease is clinically inactive and repeated infusions may be required for successful treatment.
authors.affiliation: General Army Hospital, Thessaloniki, and Medical School Democritus University of Thrace, Alexandroupolis, Greece.
authors.forename: George
authors.initials: G
authors.lastname: Kouklakis
authors.forename: John
authors.initials: J
authors.lastname: Moschos
authors.forename: Grigoris I
authors.initials: GI
authors.lastname: Leontiadis
authors.forename: Savvas
authors.initials: S
authors.lastname: Kadis
authors.forename: Alexandros
authors.initials: A
authors.lastname: Mpoumponaris
authors.forename: Epaminondas
authors.initials: E
authors.lastname: Molyvas
authors.forename: George I
authors.initials: GI
authors.lastname: Minopoulos
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000150:complications*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D017511:Pyoderma Gangrenosum / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab